Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3007851 | 0.81 | KDM4E (0.37) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3016601 | 0.77 | MAPT (0.46) | MAPTALDH1A1GAAHSD17B10SMN1; SMN2 | |
| SCHEMBL3013693 | 0.76 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3009541 | 0.75 | ALDH1A1 (0.39) | MAPTALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL3017836 | 0.72 | MAPT (0.42) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL1615657 | 0.71 | MAPT (0.45) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL24708386 | 0.69 | MAPT (0.40) | MAPTALDH1A1MEN1KMT2AGAA | |
| SCHEMBL8049474 | 0.68 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12123892 | 0.68 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL12123897 | 0.68 | MAPT (0.42) | MAPTALDH1A1KDM4EGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-2197882-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | Basf Se (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030649-A2 | METHOD FOR PRODUCING TEDA DERIVATIVES | BASF SE (DE) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204438-A1 | METHOD FOR PRODUCING TEDA DERIVATIVES | TES, TRRAP, NAAA | MAPT 1647/4885ALDH1A1 720/4885MEN1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.